La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

DermTech Crescita futura

Future criteri di controllo 0/6

Si prevede che DermTech aumenterà gli utili e i ricavi rispettivamente del 10.3% e 4.8% all'anno, mentre si prevede che l'EPS crescerà del 13.8% all'anno.

Informazioni chiave

10.3%

Tasso di crescita degli utili

13.8%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	30.0%
Tasso di crescita dei ricavi	4.8%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	22 Jul 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

May 21

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Mar 02

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Mar 02

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

May 10

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

May 06

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jan 16

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Nov 08

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Oct 11

DermTech grants stock options

Oct 11

Diving Into DermTech

Sep 01

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Aug 10

DermTech: Approaching An All Or Nothing Moment

Jun 13

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jun 04

DermTech - Taking A Second Look At The Growth Thesis

Mar 31

DermTech: Adoption Headwinds And Earnings Misses

Dec 23

Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth

Dec 02

Previsioni di crescita degli utili e dei ricavi

OTCPK:DMTK.Q - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	17	-74	N/A	N/A	1
12/31/2024	16	-74	N/A	N/A	1
3/31/2024	16	-90	-72	-72	N/A
12/31/2023	15	-101	-78	-77	N/A
9/30/2023	14	-110	-88	-86	N/A
6/30/2023	14	-120	-94	-91	N/A
3/31/2023	14	-118	-96	-92	N/A
12/31/2022	15	-117	-99	-95	N/A
9/30/2022	15	-115	-99	-97	N/A
6/30/2022	14	-106	-91	-88	N/A
3/31/2022	13	-93	-80	-76	N/A
12/31/2021	12	-78	-65	-62	N/A
9/30/2021	11	-63	-48	-46	N/A
6/30/2021	9	-52	-40	-38	N/A
3/31/2021	7	-45	-34	-32	N/A
12/31/2020	6	-36	-31	-29	N/A
9/30/2020	5	-31	-30	-28	N/A
6/30/2020	5	-27	-28	-26	N/A
3/31/2020	4	-21	-23	-22	N/A
12/31/2019	3	-20	-18	-18	N/A
9/30/2019	2	-18	-13	-13	N/A
6/30/2019	2	-14	-9	-8	N/A
3/31/2019	3	-13	-8	-8	N/A
12/31/2018	2	-10	-8	-8	N/A
12/31/2017	2	-8	N/A	-6	N/A
6/30/2014	0	-6	N/A	-4	N/A
3/31/2014	0	-6	N/A	-3	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che DMTK.Q rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che DMTK.Q rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che DMTK.Q rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di DMTK.Q ( 4.8% all'anno) crescerà più lentamente rispetto al mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di DMTK.Q ( 4.8% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di DMTK.Q è previsto essere elevato tra 3 anni

DermTech Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 26% to US$2.04

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 11% to US$3.20

Consensus EPS estimates upgraded to US$3.11 loss

Consensus revenue estimates fall by 16%

Price target decreased by 22% to US$5.75

Recent updates

DermTech, Inc.(NasdaqCM:DMTK) dropped from NASDAQ Composite Index

Nasdaq to Delist Common Stock of DermTech

Motion for Joint Administration Filed by DermTech, Inc.

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

Kilroy Realty, L.P. Files a Complaint Against DermTech, Inc. for $661,706 in Unpaid Rent

First quarter 2024 earnings released: US$0.58 loss per share (vs US$1.02 loss in 1Q 2023)

Price target decreased by 26% to US$2.04

DermTech Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Minimum Bid Price Requirement

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 11% to US$3.20

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

DermTech, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test (Dmt) Across All Skin Types

DermTech, Inc. Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-On Assay

Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test (Dmt)

Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

Pomerantz LLP Announces the Filing of A Class Action Against DermTech, Inc. and Certain Officers

Consensus EPS estimates upgraded to US$3.11 loss

Third quarter 2023 earnings: EPS exceeds analyst expectations

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against DermTech, Inc

DermTech, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DermTech, Inc. to Report Q2, 2023 Results on Aug 03, 2023

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Consensus revenue estimates fall by 16%

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

DermTech, Inc. Announces Change of CEO

Price target decreased by 22% to US$5.75

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

First quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 11% to US$7.00

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

DermTech, Inc. to Report Q4, 2022 Results on Mar 02, 2023

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

DermTech, Inc. Announces the Foundational Assay of Its DermTech Melanoma Test Is Recommended for Coverage by TRICARE

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its Dermtech Melanoma Test (Dmt)

Price target decreased to US$7.33

High number of new directors

DermTech, Inc. Announces Board Committee Appointments

Consensus forecasts updated

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

DermTech, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

DermTech grants stock options

Diving Into DermTech

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Dermtech, Inc. Provides Revenue Guidance for the Full Year 2022

DermTech, Inc. Appoints Chief Compliance Officer and SVP of Research and Development

DermTech, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Dermtech Announces New Board Appointment

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Dynamic Index

DermTech: Approaching An All Or Nothing Moment

President exercised options to buy US$59k worth of stock.

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

High number of new and inexperienced directors

DermTech, Inc. Presents New Research Differentiating Atopic Dermatitis and Psoriasis At the Society for Investigative Dermatology's Annual Meeting

DermTech, Inc. Affirms Revenue Guidance for the Full-Year 2022

DermTech, Inc., Annual General Meeting, May 26, 2022

DermTech - Taking A Second Look At The Growth Thesis